Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance

July 24, 2013 updated by: Roswell Park Cancer Institute

MR Imaging to Stratify Prostate Cancer Progression Risk in Patients on Active Surveillance

RATIONALE: Sometimes prostate cancer may not need treatment until it progresses. In this case, active surveillance may be sufficient. Diagnostic procedures, such as magnetic resonance imaging, may be a less invasive method of finding prostate cancer that has progressed.

PURPOSE: This clinical trial is studying how well magnetic resonance imaging works in detecting cancer progression in patients with early-stage prostate cancer who are undergoing active surveillance.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVES:

Primary

  • To determine if MRI parameters (initial volume, number and location of image abnormalities, and MR spectroscopy) can improve the ability to stratify cancer progression risk in patients undergoing active surveillance for early-stage prostate cancer.

Secondary

  • Determine if changes in non-invasive MRI, validated by MRI-guided biopsies, can accurately detect progression of prostate cancer.

OUTLINE: Patients undergo prostate MRI scans and MRI-guided biopsies of suspicious lesions at baseline. Patients undergo conventional anatomic imaging followed by research biological imaging tests (e.g., magnetic resonance spectroscopic imaging and/or dynamic contrast-enhanced MRI). MRI are repeated at 6 months, 1 year, and then annually until initiation of definitive therapy or for a total of 5 years.

Tissue biopsy with MRI guidance is done at baseline and annually or as clinically indicated based on change in rectal exam, PSA, or maybe done based on change in MR imaging (i.e., new MR lesion or significant change [> 25% increase] in the size of a MR lesion).

Blood samples are collected at baseline and periodically during study for PSA tests.

Study Type

Interventional

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

DISEASE CHARACTERISTICS:

  • Histologically confirmed prostate cancer

  • Low-risk for progression, as evidenced by all of the following:

    • Tumor stage ≤ T2a
    • PSA ≤ 10 ng/mL
    • Gleason score ≤ 7

  • Patients informed of treatment options and has already chosen to undergo active surveillance

    • No decision to stop active surveillance
  • No node-positive or metastatic disease

PATIENT CHARACTERISTICS:

  • Willing to undergo MRI
  • Willing to undergo prostate biopsy

  • No contraindications to MRI that include, but not limited to, any of the following:

    • Claustrophobia
    • Anxiety
    • Presence of metal or shrapnel in the body
    • Pacemakers
    • Old tattoos with metal-based dye material
  • No contraindication to prostate biopsy

  • No medical conditions, as deemed by the PI or associates, that would prevent or limit the patient participation on the protocol that include, but not limited to, any of the following:

    • Severe coagulopathy
    • History of severe bleeding
    • Severe coronary artery disease
    • Other comorbid conditions that limit life expectancy to less than 2 years

PRIOR CONCURRENT THERAPY:

  • No hormone therapy within the past year
  • No prior pelvic radiotherapy
  • No prior prostate resection including transurethral resection of prostate
  • Concurrent participation in other clinical studies (e.g., vitamin D, selenium) allowed provided active surveillance is continued

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: DIAGNOSTIC
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Prostate cancer progression measured by MRI while on active surveillance
Time Frame: at 6 months, 1 year and than annualy for 5 years
at 6 months, 1 year and than annualy for 5 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Prostate cancer changes by MRI
Time Frame: At 6months, 1 year and annually for 5 years
At 6months, 1 year and annually for 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Roswell Park Cancer Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2008

Primary Completion (ACTUAL)

July 1, 2013

Study Completion (ACTUAL)

July 1, 2013

Study Registration Dates

First Submitted

November 21, 2008

First Submitted That Met QC Criteria

November 21, 2008

First Posted (ESTIMATE)

November 24, 2008

Study Record Updates

Last Update Posted (ESTIMATE)

July 25, 2013

Last Update Submitted That Met QC Criteria

July 24, 2013

Last Verified

July 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CDR0000618738
  • RPCI-I-124107 (OTHER: Roswell Park Cancer Institute)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prostate Cancer

Clinical Trials on active surveillance

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe